bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary material from A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers
Authors: Banerji Udai , Dean Emma J. , Pérez-Fidalgo J. Alejandro , Batist Gerald , Bedard Philippe L. , You Benoit , Westin Shannon N. , Kabos Peter , Garrett Michelle D. , Tall Mathew , Ambrose Helen , Barrett J. Carl , Carr T. Hedley , Cheung S.Y. Amy , Corcoran Claire , Cullberg Marie , Davies Barry R. , de Bruin Elza C. , Elvin Paul , Foxley Andrew , Lawrence Peter , Lindemann Justin P.O. , Maudsley Rhiannon , Pass Martin , Rowlands Vicky , Rugman Paul , Schiavon Gaia , Yates James , Schellens Jan H.M.
Published: April 2023

Supplementary methods and results Supplementary Figure 1. Study 1 (NCT01226316) design Supplementary Figure 2. Dose escalation and DLTs in Part A, with MTDs of the continuous, 4/7, and 2/7 schedules being 320, 480, and 640 mg bid, respectively Supplementary Figure 3. Exploratory mutation analyses (ddPCR) in archival tissue and plasma (ctDNA) samples from a breast cancer patient who had progressive disease as best response (Cb cohort) Supplementary Figure 4. A) Tumour growth inhibition in preclinical tumor xenograft models (BT474c, HGC-27, HCC1954 and 786.0) treated with AZD5363 bid po at the indicated doses. B) AZD5363 PD in BT474c tumor xenografts. C) AZD5363 PD at steady state in BT474c xenograft tumors. D) Time course of pPRAS40 and pAkt S473 in BT474c tumor xenograft tissue following the final dose of AZD5363 after 3 weeks' continuous (100 mg/kg bid) or intermittent dosing (130 mg/kg bid 4/7 and 170 mg/kg bid 2/7) Supplementary Figure 5. Glucose (non-fasting/random) values over time after 480 mg single-dose AZD5363 (all dosing schedules) Supplementary Table 1. Percentage change from baseline for PoM biomarkers for 12 evaluable patients Supplementary Table 2. Antibodies and conditions for IHC analysis Supplementary Table 3. ddPCR primers and probes Supplementary Table 4. Tables with results of molecular analyses of Part C patients (PIK3CA and ESR1 mutation status in tissue and ctDNA, PTEN status in archival tissue) Supplementary Table 5. AEs of CTCAE grade {greater than or equal to}3 (irrespective of causality) in Parts A and B (frequency >3% total) and Part C (frequency >5% total)
Figure S1 from A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma
Authors: Gedeon Patrick C. , Schaller Teilo H. , Chitneni Satish K. , Choi Bryan D. , Kuan Chien-Tsun , Suryadevara Carter M. , Snyder David J. , Schmittling Robert J. , Szafranski Scott E. , Cui Xiuyu , Healy Patrick N. , Herndon James E. , McLendon Roger E. , Keir Stephen T. , Archer Gary E. , Reap Elizabeth A. , Sanchez-Perez Luis , Bigner Darell D. , Sampson John H.
Published: April 2023

Figure S1 - Schematic illustrating the timeline of tumor implantation, immune reconstitution, and bi-scFv treatment for the U87-MG-EGFRvIII, U87-MG, and D270 efficacy studies shown in Figure 7.
Figure S5 from Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non–Small Cell Lung Cancer
Authors: Villarroel-Espindola Franz , Yu Xiaoqing , Datar Ila , Mani Nikita , Sanmamed Miguel , Velcheti Vamsidhar , Syrigos Konstantinos , Toki Maria , Zhao Hongyu , Chen Lieping , Herbst Roy S. , Schalper Kurt A.
Published: April 2023

Expression of VISTA in immune cell subsets
Supplementary table S2 from T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling
Authors: Josefsson Sarah E. , Huse Kanutte , Kolstad Arne , Beiske Klaus , Pende Daniela , Steen Chloé B. , Inderberg Else Marit , Lingjærde Ole Christian , Østenstad Bjørn , Smeland Erlend B. , Levy Ronald , Irish Jonathan M. , Myklebust June H.
Published: April 2023

Table S2. Expression of TIGIT ligands in B cells and T cells.
Supplementary table S1 from T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling
Authors: Josefsson Sarah E. , Huse Kanutte , Kolstad Arne , Beiske Klaus , Pende Daniela , Steen Chloé B. , Inderberg Else Marit , Lingjærde Ole Christian , Østenstad Bjørn , Smeland Erlend B. , Levy Ronald , Irish Jonathan M. , Myklebust June H.
Published: April 2023

Antibodies used for flow cytometry analysis and TCR activation
Supplementary methods and references, Supplementary Figures 1-9 from T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling
Authors: Josefsson Sarah E. , Huse Kanutte , Kolstad Arne , Beiske Klaus , Pende Daniela , Steen Chloé B. , Inderberg Else Marit , Lingjærde Ole Christian , Østenstad Bjørn , Smeland Erlend B. , Levy Ronald , Irish Jonathan M. , Myklebust June H.
Published: April 2023

Supplementary Figure 1. IL-21 producô€†Ÿon is reduced in CD4 FL T cells; Supplementary Figure 2. TCR-induced signaling effectors have different kineô€†Ÿc; Supplementary Figure 3. Idenô€†Ÿficaô€†Ÿon of T-cell subsets; Supplementary Figure 4. Distribuô€†Ÿon of T-cell subsets in FL LN; Supplementary Figure 5. Expression paô€†©erns of co-inhibitory receptors in CD8 and CD4 T-cell subsets; Supplementary Figure 6. Contribuô€†Ÿon of Tregs among CD4+TIGIT+ T cells; Supplementary Figure 7. TIGIT is a highly expressed co-inhibitory receptor in FL; Supplementary Figure 8. TIGIT expression is stable over ô€†Ÿme; Supplementary Figure 9. Recovery of TCR-induced signaling in TIGIT+ CD8+ FL T cells is robust.
Supplementary figures 1-9 from T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling
Authors: Josefsson Sarah E. , Huse Kanutte , Kolstad Arne , Beiske Klaus , Pende Daniela , Steen Chloé B. , Inderberg Else Marit , Lingjærde Ole Christian , Østenstad Bjørn , Smeland Erlend B. , Levy Ronald , Irish Jonathan M. , Myklebust June H.
Published: April 2023

Supplementary Figure 1. IL-21 producô€†Ÿon is reduced in CD4 FL T cells; Supplementary Figure 2. TCR-induced signaling effectors have different kineô€†Ÿc; Supplementary Figure 3. Idenô€†Ÿficaô€†Ÿon of T-cell subsets; Supplementary Figure 4. Distribuô€†Ÿon of T-cell subsets in FL LN; Supplementary Figure 5. Expression paô€†©erns of co-inhibitory receptors in CD8 and CD4 T-cell subsets; Supplementary Figure 6. Contribuô€†Ÿon of Tregs among CD4+TIGIT+ T cells; Supplementary Figure 7. TIGIT is a highly expressed co-inhibitory receptor in FL; Supplementary Figure 8. TIGIT expression is stable over ô€†Ÿme; Supplementary Figure 9. Recovery of TCR-induced signaling in TIGIT+ CD8+ FL T cells is robust.
Supplements from IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors
Authors: Molenaar Remco J. , Radivoyevitch Tomas , Nagata Yasunobu , Khurshed Mohammed , Przychodzen Bartolomiej , Makishima Hideki , Xu Mingjiang , Bleeker Fonnet E. , Wilmink Johanna W. , Carraway Hetty E. , Mukherjee Sudipto , Sekeres Mikkael A. , van Noorden Cornelis J.F. , Maciejewski Jaroslaw P.
Published: April 2023

Supplementary Figures, Methods and Tables
Supplementary Figure 2 from Vitamin D–Binding Protein Enhances Epithelial Ovarian Cancer Progression by Regulating the Insulin-like Growth Factor-1/Akt Pathway and Vitamin D Receptor Transcription
Authors: Huang Yu-Fang , Wu Yi-Hui , Cheng Wen-Fang , Peng Shu-Ling , Shen Wan-Lin , Chou Cheng-Yang
Published: April 2023

Grading of immunohistochemistrical intensity of vitamin D binding protein (DBP) expression
Supplementary Methods from Epigenome-wide SRC-1–Mediated Gene Silencing Represses Cellular Differentiation in Advanced Breast Cancer
Authors: Ward Elspeth , Varešlija Damir , Charmsaz Sara , Fagan Ailis , Browne Alacoque L. , Cosgrove Nicola , Cocchiglia Sinéad , Purcell Siobhan P. , Hudson Lance , Das Sudipto , O'Connor Darran , O'Halloran Philip J. , Sims Andrew H. , Hill Arnold D. , Young Leonie S.
Published: April 2023

Detailed description of the materials and methods
Supplementary Methods, Supplementary References, Supplementary Figure 1, Supplementary Tables 1-3 from First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors
Authors: Hidalgo Manuel , Martinez-Garcia Maria , Le Tourneau Christophe , Massard Christophe , Garralda Elena , Boni Valentina , Taus Alvaro , Albanell Joan , Sablin Marie-Paule , Alt Marie , Bahleda Ratislav , Varga Andrea , Boetsch Christophe , Franjkovic Izolda , Heil Florian , Lahr Angelika , Lechner Katharina , Morel Anthony , Nayak Tapan , Rossomanno Simona , Smart Kevin , Stubenrauch Kay , Krieter Oliver
Published: April 2023

Supplementary Table S1. Criteria for defining dose-limiting toxicities; Supplementary Table S2. Plasma pharmacokinetic parameters of vanucizumab on Cycles 1 and 4 following bi-weekly administration of ascending doses of vanucizumab; Supplementary Table S3. Plasma pharmacokinetic parameters of vanucizumab on Cycles 1 and 4 following weekly administration of ascending doses of vanucizumab.
Table S2 from Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy
Authors: Ribba Benjamin , Boetsch Christophe , Nayak Tapan , Grimm Hans Peter , Charo Jehad , Evers Stefan , Klein Christian , Tessier Jean , Charoin Jean Eric , Phipps Alex , Pisa Pavel , Teichgräber Volker
Published: April 2023

Supplemental Table S2: Model parameter estimates. For model equations, refer to supplemental material.
Figure S1 from Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy
Authors: Ribba Benjamin , Boetsch Christophe , Nayak Tapan , Grimm Hans Peter , Charo Jehad , Evers Stefan , Klein Christian , Tessier Jean , Charoin Jean Eric , Phipps Alex , Pisa Pavel , Teichgräber Volker
Published: April 2023

Supplementary Figure S1: Left: CEA expression by immuno-histochemistry in the LS174T tumor mouse model: homogeneous cytoplasmic antigen distribution. Right: CEA expression in one of the treated patients (colorectal cancer): heterogeneous cytoplasmic antigen distribution with polarized apical accumulation.
Supplementary Table S6 from Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma
Authors: Mason Nicola J. , Gnanandarajah Josephine S. , Engiles Julie B. , Gray Falon , Laughlin Danielle , Gaurnier-Hausser Anita , Wallecha Anu , Huebner Margie , Paterson Yvonne
Published: April 2023

Necropsy findings including location of metastatic lesions, tumor type and subtype, tumor grade and HER2/neu status in ADXS31-164 treated dogs.
Supp Figure S3 from A Combination of SAHA and Quinacrine Is Effective in Inducing Cancer Cell Death in Upper Gastrointestinal Cancers
Authors: Zhu Shoumin , Chen Zheng , Wang Lihong , Peng Dunfa , Belkhiri Abbes , Lockhart A. Craig , El-Rifai Wael
Published: April 2023

Supp Figure S3
Supp Figure S2 from A Combination of SAHA and Quinacrine Is Effective in Inducing Cancer Cell Death in Upper Gastrointestinal Cancers
Authors: Zhu Shoumin , Chen Zheng , Wang Lihong , Peng Dunfa , Belkhiri Abbes , Lockhart A. Craig , El-Rifai Wael
Published: April 2023

Supp Figure S2
Fig S7 from Platelets Enhance Multiple Myeloma Progression via IL-1β Upregulation
Authors: Takagi Satoshi , Tsukamoto Shokichi , Park Jihye , Johnson Kelly E. , Kawano Yawara , Moschetta Michele , Liu Chia-Jen , Mishima Yuji , Kokubun Katsutoshi , Manier Salomon , Salem Karma Z. , Huynh Daisy , Sacco Antonio , Forward Jodi , Roccaro Aldo M. , Battinelli Elisabeth M. , Ghobrial Irene M.
Published: April 2023

IL-1b knockout MM cells were generated and confirmed.
Fig S1_NEW from Platelets Enhance Multiple Myeloma Progression via IL-1β Upregulation
Authors: Takagi Satoshi , Tsukamoto Shokichi , Park Jihye , Johnson Kelly E. , Kawano Yawara , Moschetta Michele , Liu Chia-Jen , Mishima Yuji , Kokubun Katsutoshi , Manier Salomon , Salem Karma Z. , Huynh Daisy , Sacco Antonio , Forward Jodi , Roccaro Aldo M. , Battinelli Elisabeth M. , Ghobrial Irene M.
Published: April 2023

5TGM1 cells co-localized with platelets in femur of syngeneic murine model.
Table S1 from Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer
Authors: Fu Hangcheng , Zhu Yu , Wang Yiwei , Liu Zheng , Zhang Junyu , Xie Huyang , Fu Qiang , Dai Bo , Ye Dingwei , Xu Jiejie
Published: April 2023

Univariate Cox Regression Analysis of 22 immune phenotypes and overall survival with TCGA database
Figure S5 from The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy
Authors: Puhr Martin , Hoefer Julia , Eigentler Andrea , Ploner Christian , Handle Florian , Schaefer Georg , Kroon Jan , Leo Angela , Heidegger Isabel , Eder Iris , Culig Zoran , Van der Pluijm Gabri , Klocker Helmut
Published: April 2023

Screening for PR mRNA (left) and protein (right) expression in multiple breast and prostate cancer cell lines including positive (MCF7, T47D) and negative controls (MDA MB231, BT20).
Supplementary tables from Lifetime Genistein Intake Increases the Response of Mammary Tumors to Tamoxifen in Rats
Authors: Zhang Xiyuan , Cook Katherine L. , Warri Anni , Cruz Idalia M. , Rosim Mariana , Riskin Jeffrey , Helferich William , Doerge Daniel , Clarke Robert , Hilakivi-Clarke Leena
Published: April 2023

Table S1: Ingredients of rat diets. Table S2: Responses of DMBA-induced ER+ mammary tumors to tamoxifen (TAM). Table S3. Primers used for quantitative real-time PCR
Supplementary Figure S4 from Lifetime Genistein Intake Increases the Response of Mammary Tumors to Tamoxifen in Rats
Authors: Zhang Xiyuan , Cook Katherine L. , Warri Anni , Cruz Idalia M. , Rosim Mariana , Riskin Jeffrey , Helferich William , Doerge Daniel , Clarke Robert , Hilakivi-Clarke Leena
Published: April 2023

Effect of tamoxifen (TAM) on protein levels of genes in unfolded protein response (UPR) and autophagy pathways in the mammary glands and tumors
Supplementary Figure 2 from Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response
Authors: Muckenhuber Alexander , Berger Anne Katrin , Schlitter Anna Melissa , Steiger Katja , Konukiewitz Björn , Trumpp Andreas , Eils Roland , Werner Jens , Friess Helmut , Esposito Irene , Klöppel Günter , Ceyhan Güralp O. , Jesinghaus Moritz , Denkert Carsten , Bahra Marcus , Stenzinger Albrecht , Sprick Martin R. , Jäger Dirk , Springfeld Christoph , Weichert Wilko
Published: April 2023

a)+b) Bar graphs of the distribution of histopathological grade in IHC-derived subtypes of PDAC (p-value a:0.102 b:0.986) c) Bar graph of in depth analysis of histomorphological growth patterns (PR2 cohort) and molecular subtype. Y-axis depicts total number of cases. Combined/heterogeneous growth patterns depicted with "_". CD=classic ductal.
Supplementary Materials from Relationship of the Breast Ductal Carcinoma In Situ Immune Microenvironment with Clinicopathological and Genetic Features
Authors: Hendry Shona , Pang Jia-Min B. , Byrne David J. , Lakhani Sunil R. , Cummings Margaret C. , Campbell Ian G. , Mann G. Bruce , Gorringe Kylie L. , Fox Stephen B.
Published: April 2023

Figures S1 and S2, Tables S1 and S2 Supplementary Information Supplementary Table 1. DCIS cases assessed for tumour lymphocytes Supplementary Table 2. DCIS cases assessed for PD-L1 protein expression Supplementary Figure 1. Cohort summary Supplementary Figure 2. TILs in DCIS cases comparing primary with recurrence tumours.
Table S1 from Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer
Authors: Bang Yung-Jue , Cho Jae Yong , Kim Yeul Hong , Kim Jin Won , Di Bartolomeo Maria , Ajani Jaffer A. , Yamaguchi Kensei , Balogh Agnes , Sanchez Teresa , Moehler Markus
Published: April 2023

Table S1 shows Evaluation of lesions
Figure S3B from Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes
Authors: Xochelli Aliki , Baliakas Panagiotis , Kavakiotis Ioannis , Agathangelidis Andreas , Sutton Lesley-Ann , Minga Eva , Ntoufa Stavroula , Tausch Eugen , Yan Xiao-Jie , Shanafelt Tait , Plevova Karla , Boudjogra Myriam , Rossi Davide , Davis Zadie , Navarro Alba , Sandberg Yorick , Vojdeman Fie Juhl , Scarfo Lydia , Stavroyianni Niki , Sudarikov Andrey , Veronese Silvio , Tzenou Tatiana , Karan-Djurasevic Teodora , Catherwood Mark , Kienle Dirk , Chatzouli Maria , Facco Monica , Bahlo Jasmin , Pott Christiane , Pedersen Lone Bredo , Mansouri Larry , Smedby Karin E. , Chu Charles C. , Giudicelli Véronique , Lefranc Marie-Paule , Panagiotidis Panagiotis , Juliusson Gunnar , Anagnostopoulos Achilles , Vlahavas Ioannis , Antic Darko , Trentin Livio , Montillo Marco , Niemann Carsten , Döhner Hartmut , Langerak Anton W. , Pospisilova Sarka , Hallek Michael , Campo Elias , Chiorazzi Nicholas , Maglaveras Nikos , Oscier David , Gaidano Gianluca , Jelinek Diane F. , Stilgenbauer Stephan , Chouvarda Ioanna , Darzentas Nikos , Belessi Chrysoula , Davi Frederic , Hadzidimitriou Anastasia , Rosenquist Richard , Ghia Paolo , Stamatopoulos Kostas
Published: April 2023

CLL with mutated IGHV4-34 receptors: shared and distinct clinical outcomes. B. IgG subsets #4 and #16 displayed significantly longer TTFT (p=0.00038) compared to M-CLL cases utilizing IGHV genes other than IGHV4-34.
Supplementary Table 2 from Survival and Proliferation of Neural Progenitor–Derived Glioblastomas Under Hypoxic Stress is Controlled by a CXCL12/CXCR4 Autocrine-Positive Feedback Mechanism
Authors: Calinescu Anda-Alexandra , Yadav Viveka Nand , Carballo Erica , Kadiyala Padma , Tran Dustin , Zamler Daniel B. , Doherty Robert , Srikanth Maithreyi , Lowenstein Pedro Ricardo , Castro Maria Graciela
Published: April 2023

AMD3100 decreases the proliferation of neurosphere cultures: Magnitude of Change.
Supplementary Figure 1 from A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
Authors: Yau Thomas C.C. , Lencioni Riccardo , Sukeepaisarnjaroen Wattana , Chao Yee , Yen Chia-Jui , Lausoontornsiri Wirote , Chen Pei-Jer , Sanpajit Theeranun , Camp Aaron , Cox Donna S. , Gagnon Robert C. , Liu Yuan , Raffensperger Kristen E. , Kulkarni Diptee A. , Kallender Howard , Ottesen Lone Harild , Poon Ronnie T.P. , Bottaro Donald P.
Published: April 2023

Association of NR1I3 haplotype with TTP (Supplementary Online only). CAT/CAT carriers, median TTP 1.92 months vs 6.21 months for CAT/â^' or â^'/â^' carriers.
Suppl Table 3 from The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA
Authors: Parpart-Li Sonya , Bartlett Bjarne , Popoli Maria , Adleff Vilmos , Tucker Laura , Steinberg Rebecca , Georgiadis Andrew , Phallen Jill , Brahmer Julie , Azad Nilo , Browner Ilene , Laheru Daniel , Velculescu Victor E. , Sausen Mark , Diaz Luis A.
Published: April 2023

Observed genome equivalents, wild-type DNA fragments, mutant DNA fragments, and mutant allele frequency in K2EDTA tubes at 4{degree sign}C and Streck{trade mark, serif} BCT tubes at room temperature.
Suppl Table 1 from The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA
Authors: Parpart-Li Sonya , Bartlett Bjarne , Popoli Maria , Adleff Vilmos , Tucker Laura , Steinberg Rebecca , Georgiadis Andrew , Phallen Jill , Brahmer Julie , Azad Nilo , Browner Ilene , Laheru Daniel , Velculescu Victor E. , Sausen Mark , Diaz Luis A.
Published: April 2023

Summary of clinical characteristics, plasma volume and DNA yield in 15 cancer patients.
Supplemental Materials from Detecting the Presence and Progression of Premalignant Lung Lesions via Airway Gene Expression
Authors: Beane Jennifer , Mazzilli Sarah A. , Tassinari Anna M. , Liu Gang , Zhang Xiaohui , Liu Hanqiao , Buncio Anne Dy , Dhillon Samjot S. , Platero Suso J. , Lenburg Marc E. , Reid Mary E. , Lam Stephen , Spira Avrum E.
Published: April 2023

Supplemental Methods, Tables, and Figures
Supplemental Dataset 1 from Detecting the Presence and Progression of Premalignant Lung Lesions via Airway Gene Expression
Authors: Beane Jennifer , Mazzilli Sarah A. , Tassinari Anna M. , Liu Gang , Zhang Xiaohui , Liu Hanqiao , Buncio Anne Dy , Dhillon Samjot S. , Platero Suso J. , Lenburg Marc E. , Reid Mary E. , Lam Stephen , Spira Avrum E.
Published: April 2023

Ensembl IDs for genes used to predict smoking status.
Supplementary Table S1 from Activation of EIF4E by Aurora Kinase A Depicts a Novel Druggable Axis in Everolimus-Resistant Cancer Cells
Authors: Katsha Ahmed , Wang Lihong , Arras Janet , Omar Omar M. , Ecsedy Jeffrey , Belkhiri Abbes , El-Rifai Wael
Published: April 2023

Supp Table 1
Fig. S7 from Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer
Authors: Chen Xin , Li Qiuhui , Liu Xin , Liu Can , Liu Ruifang , Rycaj Kiera , Zhang Dingxiao , Liu Bigang , Jeter Collene , Calhoun-Davis Tammy , Lin Kevin , Lu Yue , Chao Hsueh-Ping , Shen Jianjun , Tang Dean G.
Published: April 2023

TM+ phenotypic markers are required for AI tumor grwoth.
Supplementary Data from Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination
Authors: Batich Kristen A. , Reap Elizabeth A. , Archer Gary E. , Sanchez-Perez Luis , Nair Smita K. , Schmittling Robert J. , Norberg Pam , Xie Weihua , Herndon James E. , Healy Patrick , McLendon Roger E. , Friedman Allan H. , Friedman Henry S. , Bigner Darell , Vlahovic Gordana , Mitchell Duane A. , Sampson John H.
Published: April 2023

supplementary figures and legends
Supplementary Table S1 from Predicting the Grade of Dysplasia of Pancreatic Cystic Neoplasms Using Cyst Fluid DNA Methylation Markers
Authors: Hata Tatsuo , Dal Molin Marco , Hong Seung-Mo , Tamura Koji , Suenaga Masaya , Yu Jun , Sedogawa Hiraku , Weiss Matthew J. , Wolfgang Christopher L. , Lennon Anne Marie , Hruban Ralph H. , Goggins Michael G.
Published: April 2023

Supplementary Table S1. List of primers and probes
Figure S2 from Age and Gender Associations of Virus Positivity in Merkel Cell Carcinoma Characterized Using a Novel RNA In Situ Hybridization Assay
Authors: Wang Lisha , Harms Paul W. , Palanisamy Nallasivam , Carskadon Shannon , Cao Xuhong , Siddiqui Javed , Patel Rajiv M. , Zelenka-Wang Sylvia , Durham Alison B. , Fullen Douglas R. , Harms Kelly L. , Su Fengyun , Shukla Sudhanshu , Mehra Rohit , Chinnaiyan Arul M.
Published: April 2023

Read depth histograms across the Merkel cell polyomavirus (MCPyV) genome for two Merkel cell carcinoma (MCC) tumors.
Figure S1 from Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas
Authors: Pham Lan V. , Huang Shengjian , Zhang Hui , Zhang Jun , Bell Taylor , Zhou Shouhao , Pogue Elizabeth , Ding Zhiyong , Lam Laura , Westin Jason , Davis R. Eric , Young Ken H. , Medeiros L. Jeffrey , Ford Richard J. , Nomie Krystle , Zhang Leo , Wang Michael
Published: April 2023

(A) Immunoblotting of BCL-2 levels in representative MCL and DLBCL cell lines with actin as a loading control. Cell viability assays were performed using the Celltiter-Glo Luminescent Cell Viability Assay in representative GCB-DLBCL (B), non-GCB-DLBCL (C), and MCL (D) cell lines treated with increasing concentrations of venetoclax.
Table S1 from Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial
Authors: Kyi Chrisann , Roudko Vladimir , Sabado Rachel , Saenger Yvonne , Loging William , Mandeli John , Thin Tin Htwe , Lehrer Deborah , Donovan Michael , Posner Marshall , Misiukiewicz Krzysztof , Greenbaum Benjamin , Salazar Andres , Friedlander Philip , Bhardwaj Nina
Published: April 2023

Supplemental Table 1. Quantitative Immunohistochemistry (IHC). In the patient 002 with clinical benefit (stable disease, right two columns), IHC analysis of tumor showed increased CD4 (60x), CD8 (10x), PD1 (20x) and PDL1 (3x). In patients with disease (001, 004, 005, 008), quantitative IHC showed unchanged or decreased levels of CD4, CD8, PD-1, and PDL-1 over treatment periods. Individual antigens were quantified using the CRI Inform software (Perkin Elmer) which applies user-directed antigen thresholds to generate percentages normalized to the total tumor area.
Figure S3 from Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial
Authors: Kyi Chrisann , Roudko Vladimir , Sabado Rachel , Saenger Yvonne , Loging William , Mandeli John , Thin Tin Htwe , Lehrer Deborah , Donovan Michael , Posner Marshall , Misiukiewicz Krzysztof , Greenbaum Benjamin , Salazar Andres , Friedlander Philip , Bhardwaj Nina
Published: April 2023

Supplemental Figure 3. Selected BTM geneset enrichments (FDR < 0,25) of SD (patient 002) and PD patients (004 and 008) at tumor site. Gene names of enriched genesets are publicly available online in supplemental data for original paper23.
Supplementary Data from Targeting Purinergic Receptor P2Y2 Prevents the Growth of Pancreatic Ductal Adenocarcinoma by Inhibiting Cancer Cell Glycolysis
Authors: Hu Li-Peng , Zhang Xiao-Xin , Jiang Shu-Heng , Tao Ling-Ye , Li Qing , Zhu Li-Li , Yang Ming-Wei , Huo Yan-Miao , Jiang Yong-Sheng , Tian Guang-Ang , Cao Xiao-Yan , Zhang Yan-Li , Yang Qin , Yang Xiao-Mei , Wang Ya-Hui , Li Jun , Xiao Gary Guishan , Sun Yong-Wei , Zhang Zhi-Gang
Published: April 2023

Supplymentary data figure 1-8 and table 1-2
Supplementary Figure S3. Treatment profiling of PDX models from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
Authors: Zhang Leo , Nomie Krystle , Zhang Hui , Bell Taylor , Pham Lan , Kadri Sabah , Segal Jeremy , Li Shaoying , Zhou Shouhao , Santos David , Richard Shawana , Sharma Shruti , Chen Wendy , Oriabure Onyekachukwu , Liu Yang , Huang Shengjian , Guo Hui , Chen Zhihong , Tao Wenjing , Li Carrie , Wang Jack , Fang Bingliang , Wang Jacqueline , Li Lei , Badillo Maria , Ahmed Makhdum , Thirumurthi Selvi , Huang Steven Y. , Shao Yiping , Lam Laura , Yi Qing , Wang Y. Lynn , Wang Michael
Published: April 2023

Freshly isolated lymphoma cells from PT2-BL-G6 and G7 PDXs. Cell viability was tested by CellTiter-Glo luminescent cell viability assay after 48-hour incubation with the indicated drug treatment. The in vitro drug and dose information for IBN and ABT-199 are listed in Supplementary Table S1. IBN, ibrutinib; PT, patient; BL, Burkitt's lymphoma.
Supplemental Figure 3A from Exposure–Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies
Authors: Mehrotra Shailly , Gopalakrishnan Mathangi , Gobburu Jogarao , Ji Jiuping , Greer Jacqueline M. , Piekarz Richard , Karp Judith E. , Pratz Keith W. , Rudek Michelle A.
Published: April 2023

Relationship between veliparib exposure-% CFB in PAR levels in PBMC (A) and �B in PAR levels-ORR (B)
Figure S3. from Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer
Authors: Schalper Kurt A. , Carvajal-Hausdorf Daniel , McLaughlin Joseph , Altan Mehmet , Velcheti Vamsidhar , Gaule Patricia , Sanmamed Miguel F. , Chen Lieping , Herbst Roy S. , Rimm David L.
Published: April 2023

Simultaneous detection of PD-L1, IDO-1 and B7-H4 in lung cancer.
Supplemental Figure 2 from A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial
Authors: Yanagita Masahiko , Redig Amanda J. , Paweletz Cloud P. , Dahlberg Suzanne E. , O'Connell Allison , Feeney Nora , Taibi Myriam , Boucher David , Oxnard Geoffrey R. , Johnson Bruce E. , Costa Daniel B. , Jackman David M. , Jänne Pasi A.
Published: April 2023

CD45-/Cytokeratin+ positive cell as seen in the left panel, with EGFR and MET FISH shown on the same cell in the right panel. This cell would be identified as a CTC based upon CD45/cytokeratin results even though neither EGFR nor MET amplification or polysomy are seen.
Supplementary Tables and Figures from MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB
Authors: Rose April A.N. , Annis Matthew G. , Frederick Dennie T. , Biondini Marco , Dong Zhifeng , Kwong Lawrence , Chin Lynda , Keler Tibor , Hawthorne Thomas , Watson Ian R. , Flaherty Keith T. , Siegel Peter M.
Published: April 2023

Supplementary Fig. S1. Heatmap of mRNA expression for individual melanosomal differentiation antigens and a MITF transcriptional signature using a published dataset of melanoma samples (2). Supplementary Fig. S2. GPNMB expression is induced in multiple BRAF-mutant cells in response to MAPK pathway inhibition. Supplementary Fig. S3. Gene expression of MITF and GPNMB in melanoma cells following MAPK pathway inhibition. Supplementary Fig. S4. Dabrafenib and Trametinib stimulate MITF nuclear localization. Supplementary Fig. S5. Correlation of MITF and GPNMB mRNA expression in melanoma samples from patients that were on-treatment or that progressed on therapy with MAPK pathway 7 inhibitors. RT-qPCR data for MITF and GPNMB was expressed as the ratio relative to pretreatment levels. Supplementary Fig. S6. Correlation between the expression of individual melanosomal genes with MITF mRNA expression in melanoma samples from patients that were on-treatment or that progressed on therapy with MAPK pathway inhibitors. RT-qPCR data for each gene and MITF was normalized to GAPDH and expressed as the ratio relative to pre-treatment levels. Supplementary Fig. S7. MAPK pathway inhibition results in elevated levels of soluble GPNMB released from melanoma cells. Table S1: Clinical characteristics of patients biopsied for evaluation of MITF and GPNMB mRNA expression Table S2: Correlation coefficients between individual gene expression and MITF or a MITF Signature Table S3: Complete Responses Following Trametinib Treatment in Cohorts Injected with A375 or WM-2664 Melanoma Cells. Table S4: List of Primers for RT-qPCR Analyses
Supplementary Figures 1-9 from AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia
Authors: Yi Xue , Sarkar Aloke , Kismali Gorkem , Aslan Burcu , Ayres Mary , Iles LaKesla R. , Keating Michael J. , Wierda William G. , Long James P. , Bertilaccio Maria Teresa Sabrina , Gandhi Varsha
Published: April 2023

All supplementary figures
Supplemental Table 1 and 2 from Peripheral Stem Cell Apheresis is Feasible Post 131Iodine-Metaiodobenzylguanidine-Therapy in High-Risk Neuroblastoma, but Results in Delayed Platelet Reconstitution
Authors: Kraal Kathelijne C.J.M. , Timmerman Ilse , Kansen Hannah M. , van den Bos Cor , Zsiros Jozsef , van den Berg Henk , Somers Sebastiaan , Braakman Eric , Peek Annemarie M.L. , van Noesel Max M. , van der Schoot C. Ellen , Fiocco Marta , Caron Huib N. , Voermans Carlijn , Tytgat Godelieve A.M.
Published: April 2023

CD34+cell harvest yield and quality
Supplementary Table 1 from Colony-Stimulating Factor-1 Receptor Is Required for Nurse-like Cell Survival in Chronic Lymphocytic Leukemia
Authors: Polk Avery , Lu Ye , Wang Tianjiao , Seymour Erlene , Bailey Nathanael G. , Singer Jack W. , Boonstra Philip S. , Lim Megan S. , Malek Sami , Wilcox Ryan A.
Published: April 2023

Patient Characteristics (n=29)
Table S1-S13 from C8orf76 Promotes Gastric Tumorigenicity and Metastasis by Directly Inducing lncRNA DUSP5P1 and Associates with Patient Outcomes
Authors: Wang Xiaohong , Liang Qiaoyi , Zhang Lianhai , Gou Hongyan , Li Ziyu , Chen Huarong , Dong Yujuan , Ji Jiafu , Yu Jun
Published: April 2023

Table S1-S13 Table S1. Clinical and pathological characteristics of patients in two cohorts. Table S2. DNA sequences of primers used in this study. Table S3. A list shows the antibodies used. Table S4. Clinicopathologic Features of C8orf76 protein overexpression in GC. Table S5. Univariate cox regression analysis of potential poor prognostic factors for GC patients (protein). Table S6. C8orf76 protein overexpression is an independent poor prognostic factor for GC patients. Table S7. Clinicopathologic Features of C8orf76 DNA amplification in GC. Table S8. Univariate cox regression analysis of potential poor prognostic factors for GC patients (DNA copy number). Table S9. C8orf76 amplification is an independent poor prognostic factor for GC patients. Table S10. The copy number variation of C8orf76 in GC cell lines. Table S11. The sample information of PDO models. Table S12. Annotated TSS of C8orf76 binding peaks by ChIP-sequencing results. Table S13. DUSP5P1 re-expression decreased the expression of DUSPs.
Supplementary Figure legends from C8orf76 Promotes Gastric Tumorigenicity and Metastasis by Directly Inducing lncRNA DUSP5P1 and Associates with Patient Outcomes
Authors: Wang Xiaohong , Liang Qiaoyi , Zhang Lianhai , Gou Hongyan , Li Ziyu , Chen Huarong , Dong Yujuan , Ji Jiafu , Yu Jun
Published: April 2023

Supplementary Figure legends
Figure S3 from C8orf76 Promotes Gastric Tumorigenicity and Metastasis by Directly Inducing lncRNA DUSP5P1 and Associates with Patient Outcomes
Authors: Wang Xiaohong , Liang Qiaoyi , Zhang Lianhai , Gou Hongyan , Li Ziyu , Chen Huarong , Dong Yujuan , Ji Jiafu , Yu Jun
Published: April 2023

Luciferase reporter assays showed that C8orf76 didn't bind to the "attcc" motif.
Supplementary Table S3 from Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study
Authors: Peeters Marc , Price Timothy , Boedigheimer Michael , Kim Tae Won , Ruff Paul , Gibbs Peter , Thomas Anne , Demonty Gaston , Hool Kristina , Ang Agnes
Published: April 2023

Supplementary Table S3. Response and OS for RAS Mutants
Supplementary Figure 4. from PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors
Authors: Kluger Harriet M. , Zito Christopher R. , Turcu Gabriela , Baine Marina K. , Zhang Hongyi , Adeniran Adebowale , Sznol Mario , Rimm David L. , Kluger Yuval , Chen Lieping , Cohen Justine V. , Jilaveanu Lucia B.
Published: April 2023

Association between PD-L1 expression by clone 5H1 or E1L3N and TIL density.
Supplementary Figure. S3 from GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models
Authors: Shourideh Mojgan , Azabdaftari Gissou , Attwood Kristopher , DePriest Adam , Wadosky Kristine M , Gillard Bryan M , Karasik Ellen , Heemers Hannelore , Kyprianou Natasha , Gelman Irwin H. , Corey Eva , Vessella Robert L , Mohler James L. , Koochekpour Shahriar
Published: April 2023

Correlation between GRM1 and PSA in hormone-sensitive and castration-resistant LuCaP 35 xenograft model.
Supplementary Figure 1 from PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors
Authors: Kluger Harriet M. , Zito Christopher R. , Turcu Gabriela , Baine Marina K. , Zhang Hongyi , Adeniran Adebowale , Sznol Mario , Rimm David L. , Kluger Yuval , Chen Lieping , Cohen Justine V. , Jilaveanu Lucia B.
Published: April 2023

Comparison of PD-L1 expression levels across tumor types.
Supplemental Table from MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer
Authors: Dickler Maura N. , Tolaney Sara M. , Rugo Hope S. , Cortés Javier , Diéras Véronique , Patt Debra , Wildiers Hans , Hudis Clifford A. , O'Shaughnessy Joyce , Zamora Esther , Yardley Denise A. , Frenzel Martin , Koustenis Andrew , Baselga José
Published: April 2023

Supplemental Table 1. Post-discontinuation therapies
Supplementary Figure S2 from Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade
Authors: Lo Russo Giuseppe , Moro Massimo , Sommariva Michele , Cancila Valeria , Boeri Mattia , Centonze Giovanni , Ferro Simona , Ganzinelli Monica , Gasparini Patrizia , Huber Veronica , Milione Massimo , Porcu Luca , Proto Claudia , Pruneri Giancarlo , Signorelli Diego , Sangaletti Sabina , Sfondrini Lucia , Storti Chiara , Tassi Elena , Bardelli Alberto , Marsoni Silvia , Torri Valter , Tripodo Claudio , Colombo Mario Paolo , Anichini Andrea , Rivoltini Licia , Balsari Andrea , Sozzi Gabriella , Garassino Marina Chiara
Published: April 2023

Fluorescence in situ hybridization (FISH)
Figures S1-S10 from HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Authors: Hanker Ariella B. , Garrett Joan T. , Estrada Mónica Valeria , Moore Preston D. , Ericsson Paula González , Koch James P. , Langley Emma , Singh Sharat , Kim Phillip S. , Frampton Garrett M. , Sanford Eric , Owens Philip , Becker Jennifer , Groseclose M. Reid , Castellino Stephen , Joensuu Heikki , Huober Jens , Brase Jan C. , Majjaj Samira , Brohée Sylvain , Venet David , Brown David , Baselga José , Piccart Martine , Sotiriou Christos , Arteaga Carlos L.
Published: April 2023

'Fig. S1. LTR tumors maintain resistance following serial transplantation. Fig. S2. Expression of ABC transporters is not altered in LTR tumors. Fig. S3. LTR tumor-derived cell lines are sensitive to high concentrations of lapatinib + trastuzumab in vitro. Fig. S4. Identification of FGF3/4/19 amplification in an LTR tumor. Fig. S5. The combination of FGFR1 and HER2 inhibitors induces apoptosis in 11q13-amplified HER2+ cell lines. Fig. S6. Treatment with lucitanib reverses alterations in tumor microenvironment in LTR xenografts. Fig. S7. The FGFR1 inhibitor AZD4547 reverses resistance to L+T. Fig. S8. Amplification of FGF pathway genes co-occurs with ERBB2 amplification in a subset of human breast cancers. Fig. S9. CONSORT Diagram for the FinHer trial. Fig. S10. Flow diagram for samples from the NeoALTTO trial.'
Supplemental Tables 1-3 from Added Value of Serum Hormone Measurements in Risk Prediction Models for Breast Cancer for Women Not Using Exogenous Hormones: Results from the EPIC Cohort
Authors: Hüsing Anika , Fortner Renée T. , Kühn Tilman , Overvad Kim , Tjønneland Anne , Olsen Anja , Boutron-Ruault Marie-Christine , Severi Gianluca , Fournier Agnes , Boeing Heiner , Trichopoulou Antonia , Benetou Vassiliki , Orfanos Philippos , Masala Giovanna , Pala Valeria , Tumino Rosario , Fasanelli Francesca , Panico Salvatore , Bueno de Mesquita H. Bas , Peeters Petra H. , van Gills Carla H. , Quirós J. Ramón , Agudo Antonio , Sánchez Maria-Jose , Chirlaque Maria-Dolores , Barricarte Aurelio , Amiano Pilar , Khaw Kay-Tee , Travis Ruth C. , Dossus Laure , Li Kuanrong , Ferrari Pietro , Merritt Melissa A. , Tzoulaki Ioanna , Riboli Elio , Kaaks Rudolf
Published: April 2023

Supplemental Table 1 shows associations between candidate biomarkers and breast cancer risk in women postmenopausal at blood collection using 5-year risk from Pfeiffer's model as a regression offset. ORs are estimated per doubling of concentration (from log2-transformed measurements) Supplemental Table 2 shows the estimated biomarker effects on risk of breast cancer, per doubling of concentration, in women postmenopausal at blood collection. The estimates provided are adjusted for Pfeiffer's risk score from the common model (i.e. mutually adjusted) and in the selected model. Supplemental Table 3 shows the performance of the full and selected models in women postmenopausal at blood collection in terms of concordance-statistic ("C"), integrated discrimination improvement index (IDI), and net-reclassification improvement (NRI continuous), each with 95%-Confidence interval and optimism-correction from 1000 bootstrap-samples.
Appendix from A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors
Authors: Mateo Joaquin , Ganji Gopinath , Lemech Charlotte , Burris Howard A. , Han Sae-Won , Swales Karen , Decordova Shaun , DeYoung M. Phillip , Smith Deborah A. , Kalyana-Sundaram Shanker , Wu Jiuhua , Motwani Monica , Kumar Rakesh , Tolson Jerry M. , Rha Sun Young , Chung Hyun Cheol , Eder Joseph P. , Sharma Sunil , Bang Yung-Jue , Infante Jeffrey R. , Yan Li , de Bono Johann S. , Arkenau Hendrik-Tobias
Published: April 2023

Supplementary Table 1: 3 + 3 dose escalation guidelines Supplementary Table 2: Customized sequencing panel Supplementary Table 3: Summary of AEs occurring in >20% of all patients, treatment-related AEs and SAEs Supplementary Table 4: PK parameters following single dose oral dosing of GSK2636771 (PK population) Supplementary Table 5: PK parameters following single daily oral dosing of GSK2636771 (PK population) Supplementary Table 6: PK parameters following multiple dose oral dosing of GSK2636771 (PK population)
Supplementary Table S3 from Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases
Authors: Ng Charlotte K.Y. , Bidard Francois-Clement , Piscuoglio Salvatore , Geyer Felipe C. , Lim Raymond S. , de Bruijn Ino , Shen Ronglai , Pareja Fresia , Berman Samuel H. , Wang Lu , Pierga Jean-Yves , Vincent-Salomon Anne , Viale Agnes , Norton Larry , Sigal Brigitte , Weigelt Britta , Cottu Paul , Reis-Filho Jorge S.
Published: April 2023

Supplementary Table S3: Lists of validated somatic single nucleotide variants/ insertions and deletions, and amplifications/ homozygous deletions in the therapy-naÃ¯ve synchronous primary and metastatic breast cancers studied.
Supplementary Table S1 from Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases
Authors: Ng Charlotte K.Y. , Bidard Francois-Clement , Piscuoglio Salvatore , Geyer Felipe C. , Lim Raymond S. , de Bruijn Ino , Shen Ronglai , Pareja Fresia , Berman Samuel H. , Wang Lu , Pierga Jean-Yves , Vincent-Salomon Anne , Viale Agnes , Norton Larry , Sigal Brigitte , Weigelt Britta , Cottu Paul , Reis-Filho Jorge S.
Published: April 2023

Supplementary Table S1: Clinicopathologic characteristics of breast cancer patients with de novo metastastic disease included in the study.
Table S1 from Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma
Authors: Caumanns Joseph J. , Berns Katrien , Wisman G. Bea A. , Fehrmann Rudolf S.N. , Tomar Tushar , Klip Harry , Meersma Gert J. , Hijmans E. Marielle , Gennissen Annemiek M.C. , Duiker Evelien W. , Weening Desiree , Itamochi Hiroaki , Kluin Roelof J.C. , Reyners Anna K.L. , Birrer Michael J. , Salvesen Helga B. , Vergote Ignace , van Nieuwenhuysen Els , Brenton James , Braicu E. Ioana , Kupryjanczyk Jolanta , Spiewankiewicz Beata , Mittempergher Lorenza , Bernards René , van der Zee Ate G.J. , de Jong Steven
Published: April 2023

Supplementary Table 1 | Gene set for kinome sequencing.
Suppl. Figure 9 from Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance
Authors: Wartenberg Martin , Cibin Silvia , Zlobec Inti , Vassella Erik , Eppenberger-Castori Serenella , Terracciano Luigi , Eichmann Micha David , Worni Mathias , Gloor Beat , Perren Aurel , Karamitopoulou Eva
Published: April 2023

RHAMM
Suppl. Figure 8 from Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance
Authors: Wartenberg Martin , Cibin Silvia , Zlobec Inti , Vassella Erik , Eppenberger-Castori Serenella , Terracciano Luigi , Eichmann Micha David , Worni Mathias , Gloor Beat , Perren Aurel , Karamitopoulou Eva
Published: April 2023

CA19-9
Figure S6 from Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity
Authors: Tanegashima Tokiyoshi , Togashi Yosuke , Azuma Koichi , Kawahara Akihiko , Ideguchi Ko , Sugiyama Daisuke , Kinoshita Fumio , Akiba Jun , Kashiwagi Eiji , Takeuchi Ario , Irie Takuma , Tatsugami Katsunori , Hoshino Tomoaki , Eto Masatoshi , Nishikawa Hiroyoshi
Published: April 2023

Effector CD8+ T cells detected by CD44+CD62L-CD8+ T cells, PD-1+CD8+ T cells, and cytokine-producing CD8+ T cells in TILs from MC-38, MC-38-GFP, or MC-38-L2 tumors.
Supplementary Materials from A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening
Authors: Beshiri Michael L. , Tice Caitlin M. , Tran Crystal , Nguyen Holly M. , Sowalsky Adam G. , Agarwal Supreet , Jansson Keith H. , Yang Qi , McGowen Kerry M. , Yin JuanJuan , Alilin Aian Neil , Karzai Fatima H. , Dahut William L. , Corey Eva , Kelly Kathleen
Published: April 2023

Tables of compounds, recombinant proteins, antibodies, and primers used
Supplementary figure 3 from Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients
Authors: Khanna Swati , Graef Suzanne , Mussai Francis , Thomas Anish , Wali Neha , Yenidunya Bahar Guliz , Yuan Constance , Morrow Betsy , Zhang Jingli , Korangy Firouzeh , Greten Tim F. , Steinberg Seth M. , Stetler-Stevenson Maryalice , Middleton Gary , De Santo Carmela , Hassan Raffit
Published: April 2023

Mesothelioma upregulates ROS production by granulocytes
Figure S4 from Rapid Clearance Profile of Plasma Circulating Tumor HPV Type 16 DNA during Chemoradiotherapy Correlates with Disease Control in HPV-Associated Oropharyngeal Cancer
Authors: Chera Bhishamjit S. , Kumar Sunil , Beaty Brian T. , Marron David , Jefferys Stuart , Green Rebecca , Goldman Emily C. , Amdur Robert , Sheets Nathan , Dagan Roi , Hayes D. Neil , Weiss Jared , Grilley-Olson Juneko E. , Zanation Adam , Hackman Trevor , Blumberg Jeffrey M. , Patel Samip , Weissler Mark , Tan Xianming M. , Parker Joel S. , Mendenhall William , Gupta Gaorav P.
Published: April 2023

Labile ctHPV16DNA clearance kinetics in patients with low ({less than or equal to}200 copies/mL) baseline ctHPVDNA levels
Figure S6 from HERC3-Mediated SMAD7 Ubiquitination Degradation Promotes Autophagy-Induced EMT and Chemoresistance in Glioblastoma
Authors: Li Hong , Li Junjie , Chen Lei , Qi Songtao , Yu Shishi , Weng Zhijian , Hu Ziyou , Zhou Qiang , Xin Zong , Shi Linyong , Ma Liyi , Huang Annie , Lu Yuntao
Published: April 2023

The SMAD7-HERC3 binding site, and Nucleocytoplasmic shuttling and recycling of HERC3
Supplementary Methods, Tables S1-4, Figures S1-4 from Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation
Authors: Davies Jeff K. , Brennan Lisa L. , Wingard John R. , Cogle Christopher R. , Kapoor Neena , Shah Ami J. , Dey Bimalangshu R. , Spitzer Thomas R. , de Lima Marcos , Cooper Laurence J. , Thall Peter F. , Champlin Richard E. , Nadler Lee M. , Guinan Eva C.
Published: April 2023

Table S1 Patients, donors, HLA-mismatches and conditioning; Table S2 Cell doses in stem cell transplant, engraftment and chimerism; Table S3 ADLI dose and timing and allostimulator source; Table S4 Patient outcomes; Figure S1 Schema for clinical study; Figure S2 Alloanergization efficiency of DLI by centre and by dose level; Figure S3 Residual alloreactivity in aDLI and occurrence of acute GvHD after T-cell depleted haploidentical HSCT and aDLI; Figure S4 Phenotype of CD4+ regulatory T-cell (Treg) in patient peripheral blood after T-cell depleted haploidentical HSCT and aDLI
Figure S2 from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
Authors: Van Gool Inge C. , Rayner Emily , Osse Elisabeth M. , Nout Remi A. , Creutzberg Carien L. , Tomlinson Ian P.M. , Church David N. , Smit Vincent T.H.B.M. , de Wind Niels , Bosse Tjalling , Drost Mark
Published: April 2023

Spontaneous mutant frequency of Pole-mutant cell lines